Intelligence Hub | Sleuth Insights

China Biopharma Landscape: 18,000+ Assets, 335 Deals, and the Gaps

The translation gap, not the innovation gap, is the binding constraint. 18,000+ Chinese assets, 335 out-licensing deals since 2021, and ~$18B in disclosed upfronts. See Andrew Pannu's LinkedIn announcement on 4/21 to get the password.

Latest from Sleuth Intelligence

China Biopharma Landscape: 18,000+ Assets, 335 Deals, and the Gaps

STAT6 Dermatology Landscape: 39 Programs, One Clinical Leader

mTOR Non-Oncology Partnership Landscape: 144 Assets Mapped

AML Landscape: 957 Programs, 402 Targets, Opportunity Scored

The ALS Development Field Is Trapped at Two Extremes

Three GLP-1 Metabolic Blockbusters in Plain Sight

The China Biotech Partnership Funnel

Radioligand Therapy: Manufacturing Is the Primary Gate

Obesity Value Is Shifting From Efficacy to Access

Integrin α4β7 Competitive Landscape After Lilly's Morphic Acquisition

In Vivo Cell Therapy Landscape After BMS's Orbital Acquisition

Where Pharma Is Placing Early Oncology Bets

2025 Licensing Deal Trends by Therapeutic Area

Pharma Oncology Revolves Around Backbones and Modality-Agnostic Combos

Obesity Portfolio Gaps in Big Pharma

China Out-Licensing Deals YTD 2025 (July Update)

COPD Cytokine Chessboard After Back-to-Back IL-33 Failures

OXR2 Narcolepsy Landscape After Takeda's Phase 3 Readouts

RNAi Therapies Targeting Obesity

Big Pharma M&A and Licensing Deals in 2025

TL1A Global Competitive Landscape

PD-(L)1 x VEGF Global Competitive Landscape

Molecular Glue BD Landscape: $27B in Deals Since 2020

China Out-Licensing Deals YTD 2025 (February Update)

Benchmarking PD-1 Rheumatoid Arthritis Data After Rosnilimab Phase 2

PD-L1 x VEGF Market Overview: Why Only Merck Has Moved

Why Biopharma Markets Converge on Duopolies

Eli Lilly's Unique Position to Break the LOE Cycle

LOE Timing for Top Pharma Products by 2024 Sales

2024 FDA Novel Drug Approvals

Drugs Likely Selected for IRA Price Negotiation in 2027

Big Pharma Therapeutic M&A: 2019 to Present

Indication Selection Dictates Commercial Strategy

Radiopharmaceutical Portfolio Gaps in Big Pharma

Targeted Oncology Landscape: 425 Assets Across 19 Pharma

ADC M&A and IPO Activity: 2013 to Present

Grading Ten Single-Asset M&A Deals From 2016-2019

Gene Therapy Landscape: 42 Companies, 200+ Assets

How Big Pharma Valuations Trend Before and After Major LOEs

ADC Portfolio Gaps in Big Pharma

Pancreatic Cancer Treatment Landscape

Cell Therapy's Autoimmune Pivot

Five-Year Cancer Survival Rates Versus Incidence

A $50B CHIPS-Like Act for Domestic Drug Manufacturing?

Biotech Math: How the Blockbuster Model Drives Everything

Cell Therapy Landscape: 45 Companies, 400+ Programs

CDK4/6 Competition in mER+ Breast Cancer

ADC Competitive Landscape: $125B+ in Deals Since 2019

Biotech Sales Forecasts Are Wildly Off for Most Drugs

How Pharma Has Capitalized on AI: Partnerships

How Pharma Is Replacing $200B+ in Upcoming LOEs

Neuropsychiatric Therapeutics: Competitive Landscape

Biotech Has a Consolidation Problem

Why Pharma Has Stayed Away From Cell Therapy M&A

How Merck Built a Blockbuster With Keytruda

Top-Selling Drugs for Medicare Price Negotiation

How Much of Pharma's Top Assets Are Acquired Versus In-House

Obesity Drug On-Ramp Providers: Market Map

Obesity Competitive Landscape (Post-SELECT Update)

Neuro-Oncology Treatment Landscape

EGFRm+ NSCLC Treatment Landscape

Gene Editing Landscape: 42 Companies

Radiopharmaceuticals Market Map: 66 Companies

Asthma and COPD Competitive Landscape

Cell Therapy Supply Chain Market Map

RNA Therapeutics Market Map: 124 Companies

Gene Therapy Landscape (February 2023)

Notable 2023 US Drug Approvals Ranked by Sales Estimates

Notable Biopharma LOEs Through 2028

Cell Therapy Market Map: 150+ Companies

How Biotechs Can Position Obesity Assets for BD

See what your team has been missing